iOS app Android app

Gilead Sciences

April Showers Hit Markets: Bring an Umbrella to Trade

Terry Connelly | Posted 04.11.2014 | Business
Terry Connelly

Forces at work from Tokyo to Kiev have been roiling the U.S. stock market for a couple of week. But the financial sushi that is now on the menu in Japan, and Russia's "Crimea of the Century" are only part of the story.

Beating HIV: We Have the Tools, and Must Stay the Course

Philippe Douste-Blazy | Posted 01.29.2014 | Impact
Philippe Douste-Blazy

My vision is for a World AIDS Day in the near future where we can say with pride that we have achieved universal access to treatment. This goal is within reach, but only by supporting important initiatives to make medicines available, appropriate, and affordable will we fully be able to grasp it.

Truvada Truths: The Money's in the Medicine

Steve Drum | Posted 10.06.2013 | Gay Voices
Steve Drum

Truvada is just one of the family of HIV drugs produced by Gilead Sciences, which medicates about 75 percent of people treated for HIV, and all of those treatment regimens retail between $1,000 and $2,500 for 30 tablets.

Is $33,000 Too Much for a Life-Saving Drug?

Toshio Meronek | Posted 02.25.2013 | San Francisco
Toshio Meronek

People who have HIV/AIDS are able to live longer than ever before, but only if they can get their hands on the drugs. AIDS is still very much a crisis. ACT UP SF is calling for free meds for low-income people, more affordable meds for everyone, and more transparency.

Posse on Trail of Wall Street Cheats

Dan Dorfman | Posted 05.25.2011 | Business
Dan Dorfman

Financial skulduggery, judging from the latest and sharply increasing number of stock trading investigations, is unmistakably on the rise.